COVID-19无创氧疗策略的获益与风险:137家医院多中心前瞻性队列研究(COVID-ICU)
该多中心前瞻性队列研究(COVID-ICU)纳入法国、比利时、瑞士137家医院2020年2月25日至5月4日ICU收治的4754例COVID-19患者,其中1491例入ICU当日未插管,接受标准氧疗(51%)、HFNC(38%)或NIV(11%)。氧合失败(插管或ICU内未插管死亡)发生739例(50%),三组氧合失败率分别为49%、48%、60%(P < 0.001)。多因素分析显示HFNC与氧合失败减少相关(OR 0.60,95%CI 0.36-0.99,P = 0.013),NIV无此关联(OR 1.57,95%CI 0.78-3.21);90天总死亡率21%,HFNC与死亡率无关联(OR 0.90,95%CI 0.61-1.33),NIV与死亡率升高相关(OR 2.75,95%CI 1.79-4.21,P < 0.001)。作者认为需随机对照试验验证。
要点
- 1491例入ICU当日未插管的COVID-19患者中,氧合失败(插管或未插管死亡)发生739例(50%),其中插管678例、死亡61例。
- 标准氧疗、HFNC、NIV三组氧合失败率分别为49%、48%、60%(P < 0.001)。
- 多因素分析:HFNC与氧合失败减少相关(OR 0.60,95%CI 0.36-0.99,P = 0.013),NIV无此关联(OR 1.57,95%CI 0.78-3.21)。
- 90天总死亡率21%;HFNC与死亡率无关联(OR 0.90,95%CI 0.61-1.33),NIV与死亡率升高相关(OR 2.75,95%CI 1.79-4.21,P < 0.001)。
- 作者结论:HFNC与氧合失败减少相关但不改善90天死亡率,NIV与更高死亡率相关,需随机对照试验验证。
适用人群与场景
- 法国、比利时、瑞士137家医院ICU收治的COVID-19患者,入ICU当日未插管者纳入分析(1491例)。
诊断标准与关键阈值
- 氧合失败定义:插管或ICU内未插管死亡。
研究设计与关键结果
- 多中心前瞻性队列研究(COVID-ICU),137家医院,2020年2月25日至5月4日ICU收治4754例,其中1491例入ICU当日未插管,接受标准氧疗(51%)、HFNC(38%)或NIV(11%)(P < 0.001)。
- 氧合失败发生739例(50%),包括插管678例和未插管死亡61例;标准氧疗、HFNC、NIV组氧合失败率分别为49%、48%、60%(P < 0.001)。
- 多因素分析:HFNC与氧合失败减少相关(OR 0.60,95%CI 0.36-0.99,P = 0.013),NIV与氧合失败无显著关联(OR 1.57,95%CI 0.78-3.21)。
- 90天总死亡率21%;多因素分析HFNC与死亡率无关联(OR 0.90,95%CI 0.61-1.33),NIV与死亡率升高相关(OR 2.75,95%CI 1.79-4.21,P < 0.001)。
证据类型、等级与局限
- 证据类型:多中心前瞻性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论:COVID-19未插管ICU患者中,HFNC与氧合失败减少相关但不改善90天死亡率,NIV与更高死亡率相关;需随机对照试验验证。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
RATIONAL: To evaluate the respective impact of standard oxygen, high-flow nasal cannula (HFNC) and noninvasive ventilation (NIV) on oxygenation failure rate and mortality in COVID-19 patients admitted to intensive care units (ICUs).
METHODS: Multicenter, prospective cohort study (COVID-ICU) in 137 hospitals in France, Belgium, and Switzerland. Demographic, clinical, respiratory support, oxygenation failure, and survival data were collected. Oxygenation failure was defined as either intubation or death in the ICU without intubation. Variables independently associated with oxygenation failure and Day-90 mortality were assessed using multivariate logistic regression.
RESULTS: From February 25 to May 4, 2020, 4754 patients were admitted in ICU. Of these, 1491 patients were not intubated on the day of ICU admission and received standard oxygen therapy (51%), HFNC (38%), or NIV (11%) (P < 0.001). Oxygenation failure occurred in 739 (50%) patients (678 intubation and 61 death). For standard oxygen, HFNC, and NIV, oxygenation failure rate was 49%, 48%, and 60% (P < 0.001). By multivariate analysis, HFNC (odds ratio [OR] 0.60, 95% confidence interval [CI] 0.36-0.99, P = 0.013) but not NIV (OR 1.57, 95% CI 0.78-3.21) was associated with a reduction in oxygenation failure). Overall 90-day mortality was 21%. By multivariable analysis, HFNC was not associated with a change in mortality (OR 0.90, 95% CI 0.61-1.33), while NIV was associated with increased mortality (OR 2.75, 95% CI 1.79-4.21, P < 0.001).
CONCLUSION: In patients with COVID-19, HFNC was associated with a reduction in oxygenation failure without improvement in 90-day mortality, whereas NIV was associated with a higher mortality in these patients. Randomized controlled trials are needed.
参考来源
- Benefits and risks of noninvasive oxygenation strategy in COVID-19: a multicenter, prospective cohort study (COVID-ICU) in 137 hospitals. Crit Care. 2021. PMID: 34879857. doi:10.1186/s13054-021-03784-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。